吡喃阿霉素(THP—ADR)与阿霉素治疗恶性肿瘤的临床对照观察

A COMPARATIVE STUDY Oh THP-ADRIAMYCIN (THP-ADR) AND ADRIAMYCIN IN CANCER TREATMENT

吡喃阿霉素系1979年日本学者梅泽滨夫等半合成的新蒽环类抗瘤抗生素,系在阿霉素的4’-0位上接上四氢吡喃基而成。本文报告我国三家医院试用吡喃阿霉素联合化疗治疗55例恶性肿瘤,包括非何杰金氏淋巴瘤、小细胞型肺癌、乳癌及头颈部癌;另55例相应肿瘤应用阿霉素联合化疗作对照观察。结果表明,吡喃阿霉素联合化疗与阿霉素联合化疗的疗效(CR率及总缓解率)无差异,吡喃阿霉素引起的脱发比阿霉素明显较少见。吡喃阿霉素引起的Ⅰ度白细胞下降较多,但Ⅲ-Ⅳ度白细胞减少较少见,胃肠道反应无大差别,因观察时间短,两组均未见明显心脏毒性。

55 cases of various malignancies including NHL, Breast Ca, SCLC,and Head and Neck cancers were treated with THP-ADR combination chemotherapy, while 55 equivalent cases were treated with conventional ADR combinations as control group. The CR rate, Overall Response Rate of the 2 groups were almost identical In THP-ADR group patients experienced more grade I leucopenia and nausea/vomiting but less Grade 3-4 leucopenia The most remarkable difference was that in THP-ADR group alopecia was far less than in the ADR control group. No cardiotoxicity was observed in both groups, since the cuma,lative dosage administered was relatively low.